Biological Lattice Industries has secured USD 1.8 million in upfront funding, led by Uni.Fund. With BioLoom and Loominus Studio, BLI introduces an integrated 3D bioprinting solution that simplifies complex biofabrication workflows and makes research more accessible worldwide.
BLI, a US startup with research and development facilities in Greece, aims to simplify biofabrication for the global research and development community. Intelligent, automated tools are intended to make the design, production and testing of biomaterials more efficient. These biomaterials are essential for a wide range of biological applications, from advanced 3D cell culture systems to resorbable medical devices and drug delivery systems for tissue repair.
“We are thrilled to partner with Uni.Fund to bring our vision of democratizing biofabrication to life,” said Filippos Tourlomousis, Founder and CEO of BLI. “This funding will allow us to accelerate the development of our unified platform, enabling researchers to work with greater precision, reproducibility, and efficiency.”
Loominus Studio integrates all aspects of the biofabrication process, from planning to production, and enables the automation of complex workflows.
“Loominus Studio represents a new standard in biofabrication, allowing labs to focus on innovation rather than the technical challenges of integration,” said Filippos Tourlomousis. “Our goal is to make biofabrication as simple and intuitive as possible, empowering researchers to break through technical barriers.”
BioLoom is a versatile 3D bioprinter that can produce high-resolution, multi-material structures. With its active environmental control feature, BioLoom ensures reproducibility and supports good manufacturing practice (GMP) compliance, making it ideal for labs seeking rapid commercialization in the life sciences.
“BioLoom provides an unparalleled level of versatility and precision,” added Tourlomousis. “It is designed to meet the needs of both academic and commercial labs, pushing the boundaries of biofabrication beyond traditional 3D bioprinting capabilities.”
“BLI is a game-changer in the biotech space, with a bold vision to disrupt how biofabrication is performed globally,” said Katerina Pramatari, Founding Partner at Uni.Fund. “Their integrated approach to life sciences R&D, combining sophisticated hardware and software powered by AI, is exactly the kind of innovation that Uni.Fund aims to support.”
With the new funding, BLI plans to accelerate the market launch of BioLoom and Loominus Studio and to deploy the biofabrication solutions in leading academic laboratories. This should further advance the future development and application of 3D bioprinting technologies.
Subscribe to our Newsletter
3DPresso is a weekly newsletter that links to the most exciting global stories from the 3D printing and additive manufacturing industry.